Sorry, you need to enable JavaScript to visit this website.
Home About Programs & Policies Grants Investigator Sponsored Research Inflammation and Immunology Areas of Interest

Inflammation and Immunology Areas of Interest

Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.pfizer.com/ISR. A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. A formal notification regarding the status of your application will be sent once a decision is reached. Pfizer support will only be extended upon the execution of a research agreement. For any questions, please send an email to [email protected].

  • Atopic Dermatitis (AD)

    Research areas to be considered for Pfizer support include:

    • Basic and clinical research to further characterize the various endotypes and phenotypes of AD and their response to AD treatments
    • Non-interventional studies (including epidemiological studies) to examine comorbidities associated with AD, disease burden, costs and unmet need for new treatments
    • Mechanistic insights into the role of JAK/STAT pathway in AD
    • Inflammatory and non-inflammatory diseases and conditions with potential benefit from systemic inhibition of the JAK-1 pathway
    • Mechanistic insights into the role of the JAK/STAT pathway in inflammatory and non-inflammatory skin diseases
    • Clinical research into the use of JAK-1-inhibitors in AD and other inflammatory and non-inflammatory conditions (e.g. dermatologic diseases, including, but not limited to, eczematous disorders, connective tissue diseases, autoimmune blistering disorders, lichenoid eruptions, granulomatous dermatoses, neutrophilic dermatoses, cutaneous vasculitides, alopecia, scarring alopecias, prurigo nodularis, and chronic prurigo of unknown origin.)
    • Optimization of healthcare delivery for patients with moderate-severe AD

    Out of Scope:

    • Underpowered studies, or those that overlap with completed, ongoing and planned research
    • Use in non- dermatologic conditions
  • Atopic Dermatitis (AD)

    Research areas to be considered for Pfizer support include:

    • Basic and clinical research to further characterize the various endotypes and phenotypes of Atopic Dermatitis (AD) and their response to AD treatments
    • Mechanistic insights into the role of PDE-4 and/or JAK/STAT pathways in AD
    • Inflammatory and non-inflammatory diseases and conditions with potential benefit from topical application of a PDE-4-inhibitor
    • Mechanistic research on the role and effect of PDE-4 or its inhibition in skin diseases and conditions
    • Clinical research of PDE-4-inhibition in inflammatory skin diseases and conditions
    • Real-world applications of crisaborole in AD management
    • Non-interventional studies (including epidemiological studies) to examine comorbidities associated with AD, treatment patterns, disease burden, costs and unmet need for new treatments

    Out of Scope:

    • Underpowered studies, or those that overlap with completed, ongoing and planned research
    • Use in non - dermatologic conditions
  • Alopecia Areata (AA)

    Research areas to be considered for Pfizer support include:

    • Basic and clinical research to further characterize the various endotypes and phenotypes of AD and their response to AA treatments
    • Non-interventional studies (including epidemiological studies) to examine comorbidities associated with AA, disease burden, costs and unmet need for new treatments
    • Mechanistic insights into the role of JAK3 and TEC inhibition pathways in AA
    • Inflammatory and non-inflammatory diseases and conditions with potential benefit from systemic inhibition of the JAK3/TEC pathway
    • Mechanistic insights into the role of JAK3 and TEC pathways in skin diseases
    • Clinical research into the use of JAK3 and TEC inhibition in skin diseases
    • Focus on the unmet need, burden of disease, and epidemiology of AA and Vitiligo

    Out of Scope:

    • Underpowered studies, or those that overlap with completed, ongoing and planned research
    • Use in non-dermatologic conditions
  • Rheumatoid Arthritis (RA): 

    • Mechanistic research into the role of JAK and TNF inhibition in relation to the occurrence of adverse events such as venous thromboembolism (VTE), major adverse cardiovascular events (MACE) and malignancy
    • Evaluate safety and efficacy in patients with comorbidities and special/sub-populations 
    • Treatment optimization: concomitant medication dose reduction or increase, dose optimization (including tapering after remission/ low disease activity, stop and retreat), switching (to/from biologic disease-modifying antirheumatic drugs (bDMARDs) / targeted synthetic disease-modifying antirheumatic drugs tsDMARDs)
    • Evaluation of treat-to-target approach to achieve disease remission 
    • Effect on onset, sustainability, effectiveness, and health-related quality of life (especially pain and fatigue)
    • Efficacy and safety in extra-articular manifestations
    • Investigate efficacy and safety as monotherapy 
    • Evaluation of approaches for the management of viral infections or vaccinations in RA patients and treatment outcomes
    • Explore imaging studies to further help characterize the response to treatment or to help predict long-term outcomes
    • Evaluation of adherence to risk management interventions for comorbidities such hyperlipidemia, anticoagulants etc.

    Out of Scope:

    • Underpowered studies, or those that overlap with currently planned Phase 3b or Phase 4 or ongoing non-interventional studies (NIS)
    • Combination with biologics/immunosuppressants

    Ankylosing Spondylitis: 

    • Efficacy and safety of JAKi across axial spondyloarthritis spectrum of disease, different populations and across lines of therapy
    • Evaluate clinical, biomarker and imaging predictors of response and non-response to treatment and adverse events
    • Evaluate long-term safety and efficacy of the use of JAKi 
    • Assess treatment adherence and persistence of JAKi
    • Characterize JAKi relative to other advanced treatments across clinical outcomes
    • Understand efficacy/safety across patient populations including in patients with common comorbidities and different cardiovascular risk profiles
    • Explore improvement in extra-musculoskeletal manifestations (uveitis, psoriasis, inflammatory bowel disease (IBD)) and peripheral disease
    • Assess treatment scenarios such as non-steroidal anti-inflammatory drug (NSAID) sparing, treatment interruption/recapture or treatment switch (to/from NSAIDs/ bDMARDs / tsDMARDs)

    Out of Scope:

    • Underpowered studies, or those that overlap with completed, ongoing and planned research
    • Combination with biologics/immunosuppressants 

    Psoriatic Arthritis (PsA): 

    • Efficacy and safety of JAKi across domains of disease, different populations and lines of therapy
    • Characterize JAKi efficacy/safety relative to other advanced treatments across clinical outcomes referring to capturing efficacy /safety across the domains of PsA (peripheral arthritis, skin/nails, enthesitis, dactylitis and axial domain)
    • Understand efficacy/safety across patient populations including in patients with common comorbidities and different cardiovascular risk profiles
    • Study treatment adherence and persistence of JAKi
    • Investigate the safety and efficacy of JAKi in the treatment of axial PsA
    • Understand clinical, biomarker and imaging predictors of response and non-response to treatment and adverse events
    • Assess treatment scenarios such as steroid sparing, treatment interruption/recapture or treatment switch (to/from conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)/ bDMARDs / tsDMARDs)
    • Explore improvement in extra-musculoskeletal manifestations (uveitis, IBD)

    Out of Scope:

    • Underpowered studies, or those that overlap with completed, ongoing and planned research
    • Combination with biologics/immunosuppressants

    Ulcerative Colitis:

    • Disease management in ulcerative colitis (UC) using tofacitinib and new measures of efficacy (e.g., treat to target, measures of efficacy, development of new tools for patient reported outcomes (PRO) measurement using wearables/apps)
    • Use of tofacitinib in:
      • Other inflammatory gastrointestinal conditions such as eosinophilic gastroenteritis and microscopic colitis
      • UC patients with history of cancer (efficacy and safety)
    • Evaluation of the ability to restart tofacitinib therapy after interruption in patients with UC
    • Tofacitinib monotherapy (without concomitant 5 aminosalicylic acids (ASA) or steroids)
    • Strategies to improve adherence to therapies in UC and predictors of adherence
    • Contextualization of VTE/ major adverse cardiovascular event (MACE)/Malignancies risk of Tofacitinib/JAKi in patients with UC
    • Predictors of Adverse events (e.g., lipids elevation, MACE, non-melanoma skin cancer (NMSC), herpes zoster (HZ), serious infections, VTE)
    • Predictors of disease severity
    • Predictors of early response to tofacitinib using combination of biomarkers, patient-related outcomes and clinical assessments
    • Mechanistic association of JAK inhibition with safety events of special interest
    • Effects of vaccination on tofacitinib treatment
    • Evaluation of onset of action across measures of effectiveness including PROs
    • Effect of tofacitinib on extra intestinal manifestations (EIM)
    • Tofacitinib safety in the context of  
    • Tofacitinib and steroid free remission, long term remission and maintenance of response
    • Use of tofacitinib in checkpoint inhibitor/immunotherapy-induced colitis

    Out of Scope:

    • Underpowered studies, or those that overlap with completed, ongoing and planned research
    • Combination with biologics/immunosuppressants